Quick Facts: Intal (Cromolyn Sodium)

• Support for managing bronchial asthma
• Helps prevent symptoms of exercise-induced or allergen-related bronchospasm
• May be used for systemic mast cell disease (mastocytosis) in specific formulations
• Assists in the long-term management of certain allergic eye conditions

Intal (cromolyn sodium) is a prophylactic agent used to support the continuous management of specific respiratory and allergic conditions. For individuals with bronchial asthma, regular administration can assist in preventing the frequency and severity of symptoms.

This medication is also utilized to help prevent acute bronchospasm—or difficulty in breathing—that follows exposure to specific triggers, such as exercise, cold air, or environmental pollutants. For this use, the medication is administered shortly before the anticipated exposure. Intal is also indicated as an adjunctive therapy for managing the symptoms of systemic mast cell disease (mastocytosis), which may manifest as diarrhea, abdominal discomfort, and skin symptoms, based on the formulation used.

Patients should be aware that the intended effect is generally observed after several weeks of consistent use. It is important to note that this agent is used for prevention and does not provide immediate relief for an acute asthma episode.

Eligibility and Restrictions for Intal (Sodium Cromoglycate)

The determination of who can and cannot use Intal is defined strictly by official government regulatory labels.

---

Contraindications and Prohibitions

Use of Intal is contraindicated in patients with a known hypersensitivity or allergy to cromolyn sodium or to any of the specific ingredients in the preparation. Intal is a preventative medication and has no established role in the treatment of an acute asthma attack or status asthmaticus.

Age-Group Eligibility

Eligibility for pediatric patients varies by formulation. The Inhalation Aerosol (Inhaler) is approved for use in patients mathbf5 years of age and older, while the Inhalation Solution (Nebulizer) is approved for patients mathbf2 years of age and older. Use is not established and not generally recommended for children under these minimum ages. For older adults (65 and over), clinical studies did not include sufficient numbers to establish differential safety or efficacy.

Conditional Use and Caution

The medicine must be used with caution in patients with a history of cardiac arrhythmias. Furthermore, in patients with impaired renal function or impaired hepatic function, caution should be exercised and consideration should be given to a potential dosage decrease or discontinuation. The official status for use during pregnancy is US FDA Pregnancy Category B, meaning it should be used only if clearly needed. Caution is also advised when administering to a nursing woman, as it is unknown if the drug is excreted in human milk.

Interactions with other medicines and products — official regulatory information for Intal (Sodium Cromoglycate)

Interaction Scope

Category	Officially Documented Information
Medicinal product categories with documented interactions:	Other drugs in a nebulizer.
Specific interacting medicines (if explicitly listed):	None explicitly listed in regulatory labels as having formal systemic interactions.
Mechanistic basis of interactions (only if stated in label):	Pharmaceutical incompatibility for co-mixed nebulized drugs; altered clearance risk in specific populations (hepatic/renal function).
Timing-based interaction rules (if applicable):	Mandatory timing rule for the oral solution formulation requires administration 30 minutes prior to meals and at bedtime.
Population-specific interaction notes (if applicable):	Patients with Impaired Renal Function and Impaired Hepatic Function are noted for required assessment of dosage adjustment or discontinuation.
Interaction-related restrictions:	Prohibition of co-mixing Intal Nebulizer Solution with other drugs in the nebulizer; prohibition of mixing the oral solution with milk or fruit juice.

Interaction Classifications (High-Level)

Category	Officially Documented Information
Interaction severity classification (as defined in official documents):	Compatibility/Procedure Restriction; Clearance/Dose Adjustment Required; Administration Timing Requirement.
Regulatory basis (EMA / FDA / etc.):	Primarily documented in FDA Prescribing Information and SmPCs for various formulations.
Interaction-context constraints (as defined in official documents):	Constraints are limited to the Method of Administration (nebulizer mixing, oral timing) and the Patient’s Physiological State (hepatic/renal function).

Resulting interaction structure

Official interaction statements:

• The stability and safety of mixing Intal Nebulizer Solution with other drugs in a nebulizer have not been established in official regulatory documentation.
• Regulatory labels note that consideration should be given to decreasing the dosage or discontinuing the administration in patients with impaired renal or hepatic function due to altered clearance risk.
• The oral solution formulation is subject to a specific timing rule requiring it to be taken 30 minutes before each meal and at bedtime.
• Formal contraindicated combinations or systemic metabolic interactions are not documented across major regulatory labels.

Connection to the overall interaction profile: The regulatory interaction profile is defined by the absence of major systemic drug–drug interactions, consistent with its minimal systemic exposure. Documented constraints center on ensuring proper administration, including procedural restrictions against co-mixing the nebulizer solution, and an official precaution for altered drug clearance in patients with documented hepatic or renal impairment.

Intal, containing cromolyn sodium, functions as a mast cell stabilizer, primarily targeting mast cells located within the respiratory mucosa. The molecular interaction involves the inhibition of the cellular degranulation cascade that is typically initiated upon exposure to an antigen. This pharmacological action prevents the exocytosis of pre-formed and newly generated inflammatory mediators, including histamine and leukotrienes.

The precise molecular pathway involves the modulation of calcium ion flux across the mast cell membrane. Cromolyn sodium acts indirectly to block the rapid influx of extracellular calcium required for the fusion of secretory granules with the cell membrane. By inhibiting this Ca^2+-dependent signal, the release of inflammatory chemicals is abrogated. Downstream of this molecular action, the concentration of mast cell-derived mediators in the local microenvironment remains low, resulting in a systemic physiological consequence of dampened inflammatory cell recruitment and reduced non-specific bronchial hyperreactivity.

How to Use Intal (Cromolyn Sodium) — Administration Guidelines

Intal (cromolyn sodium) is available in several forms, including an Inhalation Aerosol (MDI), Inhalation Solution (Nebulizer), and Oral Solution. The correct method of administration is strictly determined by the specific product form.

---

Standard Dosing Regimens

Form and Route	Adult/Adolescent Standard Dose	Frequency and Timing
Inhalation Aerosol	Two metered inhalations	Four times daily at regular intervals (every 4–6 hours).
Inhalation Solution	20 mg (one ampule) via nebulizer	Four times daily at regular intervals (every 4–6 hours).
Oral Solution	200 mg (two ampules)	Four times daily: 30 minutes before meals and at bedtime.

---

Preparation and Procedural Rules

Oral Inhalation: For the aerosol, the inhaler must be shaken gently before use. When inhaling, the user must first exhale completely, then breathe in slowly and deeply while pressing the canister, and hold their breath for several seconds. If a second puff is required, wait about one minute between inhalations.

Nebulization: The Inhalation Solution must be administered using a power-operated nebulizer with an adequate airflow rate; hand-operated nebulizers are not suitable. The contents of one ampule are squeezed entirely into the nebulizer chamber.

Oral Solution: The contents of the ampule(s) must be diluted in a glass of water before drinking. Users must drink the entire liquid; the solution must not be mixed with fruit juice, milk, or food.

Special and Age-Specific Use

• Prophylactic Timing: For preventing acute symptoms from triggers like exercise, the dose (two inhalations or one nebulizer ampule) must be administered shortly before exposure (e.g., within 10 to 15 minutes).
• Pediatric Use: The Inhalation Aerosol is not established for children younger than five years of age, and the Inhalation Solution is not established for children younger than two years of age.
• Missed Dose: If a routine dose is missed, the next dose should be taken at the regularly scheduled time. Do not double the dose to catch up.
• Course Duration: The drug's full effect is dependent upon its administration at regular intervals, and maximum benefit may take up to four weeks of continuous use to be fully realized.

Research Evidence / Overview of Studies for Intal

---

Evidence for Prophylactic Management in Chronic Asthma

The foundational research for inhaled Intal largely involves Randomized Controlled Trials (RCTs) and systematic reviews, many of which were conducted in earlier decades. These studies examined its role as a preventative approach, meaning research explored its administration for continuous management of symptoms, rather than for the immediate relief of acute episodes. Researchers examined outcomes related to pulmonary function measures, such as FEV1 and PEFR, alongside patient-reported outcomes describing perceived discomfort, like daily asthma symptom scores and the documentation of rescue medication use.

Studies included populations of adults and children with asthma, generally categorized as mild to moderate. Research was observed in controlled settings, where findings described patterns in the frequency and severity of symptoms and changes measured during the study period (often 8 to 16 weeks). However, the field has evolved significantly. Some systematic reviews suggest that evidence quality varies across studies, and one major review focused on children described the potential for publication bias—where studies with less favorable outcomes may not have been published—which was associated with an overestimation of perceived positive results in the available literature.

---

Evidence for Preventing Exercise-Induced Bronchospasm (EIB)

Research examining the use of Intal for preventing breathing difficulty associated with exercise focuses on acute challenge trials. These are short-term studies where the agent was evaluated in subjects immediately before they performed a standardized physical activity that triggers symptoms. The studies primarily measured the maximum percent fall in FEV1 following the exercise challenge. This is an objective measure used to capture temporary physiological imbalance.

Evidence is consistent for this specific scenario when the agent is applied in studies examining short-term or episodic symptom patterns. However, the results apply only to the populations studied in these acute settings, and follow-up durations were limited to the immediate post-exercise period.

---

Key Uncertainties and Research Gaps

Overall, the research for Intal highlights several areas where certainty remains low or where research is ongoing:

• Comparative evidence is lacking against newer classes of medications that are now considered standard therapeutic approaches for asthma.
• Evidence is limited in its consistency regarding effects on non-specific bronchial hyperresponsiveness.
• The research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

Key Studies & References Cromolyn Sodium Inhalation Solution, USP (FDA DailyMed Monograph, provides indications and regulatory context for asthma management)

Common questions about Intal (FAQ)

---

Q: Can I use the Intal Oral Solution with common beverages like orange juice or milk, or does it have to be water?

The official product information states that the oral solution must be diluted in a half glass of water. Official guidance indicates the solution must not be mixed with milk, fruit juice, or food. For the full dose to be received, the product information recommends the entire liquid should be consumed.

---

Q: What are the most common side effects or adverse reactions reported with Intal?

Regulatory documents indicate that the most common side effects are generally mild and local. These commonly reported effects, as listed in the label, include cough, throat irritation, dry mouth, nausea, and headaches. The product label notes a risk of rare but serious reactions, including severe hypersensitivity (like anaphylaxis) and a sudden worsening of breathing (paradoxical bronchospasm).

---

Q: What are the key differences between the aerosol inhaler and the nebulizer solution, especially for children?

The aerosol inhaler and the nebulizer solution are different forms of the drug. The Inhalation Aerosol (MDI) has established use for patients 5 years of age and older. In contrast, the Inhalation Solution (nebulizer) is approved for use in patients 2 years of age and older. They also differ in administration, as the nebulizer solution requires a power-operated machine to create a mist.

---

Q: Does Intal need to be stored in the refrigerator or can it be kept at room temperature?

According to official regulatory sources, Intal Inhalation Solution should be stored at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F). The medication is not required to be refrigerated. Official storage instructions advise keeping the medicine in its original packaging and protecting it from light until immediately before use.

---

Q: How do I know if I have the Inhalation Aerosol (MDI) versus the Inhalation Solution (Nebulizer)?

The two forms are supplied differently. The Inhalation Aerosol (MDI) comes as a pressurized canister used for a puff of medicine. The Inhalation Solution (Nebulizer) is packaged in small, single-use liquid vials or ampules that are designed to be poured into a separate, power-operated nebulizer machine to create a breathable mist.

---

Q: What is the recommended duration of treatment for Intal (e.g., is it for short-term use, or is it long-term maintenance)?

Official information indicates that Intal is a prophylactic agent, meaning it is used for prevention. It is intended for patients who require a continuous regimen of medications for the management of their asthma symptoms. The drug is intended for regular, long-term daily use rather than for short-term or temporary relief.

Storage and Disposal of Intal (Cromolyn Sodium Inhalation Solution)

Official Storage Conditions

Intal must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The solution must be protected from light; therefore, unit-dose vials should remain in the original foil pouch until immediately before use. Do not use the medication if it appears cloudy, discolored, or contains a precipitate.

Child Safety and Disposal

Keep this and all medications out of the reach of children. Each vial is intended for immediate, single use, and any unused contents should be discarded after administration. Disposal of unused or expired Intal must comply with local regulations and should not be flushed down a toilet or drain, as recommended by official governmental guidelines.